Oncternal Therapeutics' Series B Round

Oncternal Therapeutics raised a round of funding on June 08, 2016. Investors include Hale BioPharma Ventures.

Oncternal Therapeutics, formerly Tokalas, is a clinical-stage oncology company developing therapies for both rare and common cancers by focusing on targets that are uniquely expressed within cancer ce…

Articles about Oncternal Therapeutics' Series B Round: